Literature DB >> 12126764

Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats.

Tetsuji Yamashita1, Kenichi Shikata, Mitsuhiro Matsuda, Shinichi Okada, Daisuke Ogawa, Hikaru Sugimoto, Jun Wada, Hirofumi Makino.   

Abstract

Stable prostacyclin analogue, beraprost sodium (BPS) has recently been reported to attenuate glomerular hyperfiltration in diabetic rats, however, the mechanism has been still unknown. We previously reported that overexpression of endothelial cell nitric oxide synthase (ecNOS) in afferent arterioles and glomeruli induce inappropriate dilatation of afferent arterioles and glomerular hyperfiltration through overproduction of nitric oxide in early stage of diabetic nephropathy. In this study, we tested the hypothesis that BPS ameliorates glomerular hyperfiltration through modulating ecNOS expression in diabetic nephropathy. Furthermore, we examined the effects of BPS on the expression of intercellular adhesion molecule-1 (ICAM-1) and macrophage infiltration in diabetic glomeruli, because glomerular hyperfiltration induces the expression of ICAM-1 resulting in macrophage infiltration. Male Sprague-Dawley (SD) rats were administered continuously with BPS for 4 weeks after induction of diabetes by streptozotocin. In diabetic rats, the diameters of afferent arterioles, glomerular volume, creatinine clearance and urinary excretion of albumin and NO2/NO3 were increased as compared with non-diabetic control rats. Treatment with BPS improved these changes. The expression of ecNOS was increased in afferent arterioles and glomeruli in diabetic rats and suppressed by BPS. Prostacyclin receptor was expressed along afferent arterioles. Our results suggest that BPS attenuates glomerular hyperfiltration by modulating ecNOS expression in early stage of diabetic nephropathy. Moreover, BPS may inhibit ICAM-1-dependent infiltration of macrophages in diabetic glomeruli.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126764     DOI: 10.1016/s0168-8227(02)00054-2

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

1.  The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I2 analog on the progression of sclerotic glomerulonephritis in rats.

Authors:  Yukiko Nozawa; Ayako Sato; Hoglan Piao; Tetsuo Morioka; Ichiei Narita; Takashi Oite
Journal:  Clin Exp Nephrol       Date:  2011-12-07       Impact factor: 2.801

2.  The urinary levels of prostanoid metabolites predict acute kidney injury in heterogeneous adult Japanese ICU patients: a prospective observational study.

Authors:  Haruyo Ujike-Omori; Yohei Maeshima; Masaru Kinomura; Katsuyuki Tanabe; Kiyoshi Mori; Hiroyuki Watatani; Norikazu Hinamoto; Hitoshi Sugiyama; Yoshiki Sakai; Hiroshi Morimatsu; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2015-02-11       Impact factor: 2.801

Review 3.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.

Authors:  Imari Mimura; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 4.  The Role of Platelets in Diabetic Kidney Disease.

Authors:  Ukhti Jamil Rustiasari; Joris J Roelofs
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

5.  The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats.

Authors:  Nahoko Sato; Masayuki Kaneko; Mitsutaka Tamura; Hajimu Kurumatani
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

6.  Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria.

Authors:  Yun Mi Choi; Hyuk Sang Kwon; Kyung Mook Choi; Won Young Lee; Eun Gyoung Hong
Journal:  Endocrinol Metab (Seoul)       Date:  2019-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.